The proposed project aims to build a diagnostic test for chronic T. cruzi infection and Chagas disease that not only improves testing performance but that can be readily integrated with similarly developed tests for most clinically important parasitoses. Current assays for Chagas disease, and other parasitic infections, lack desired levels of specificity, and require multiple independent assays and testing formats. Consequently, testing a single specimen for several different clinically important parasitic diseases becomes cost prohibitive and time consuming, delaying disease detection and treatment. We propose to address this problem by creating a single, all-in-one diagnostic test able to detect ten or more different clinically important parasitic diseases. Importantly, the proposed strategy could be expanded to a nearly arbitrary number of infectious diseases without resultant increases in final test cost. Towards a multiplexed parasitic disease test, we will first create an improved test for Chagas disease, that impacts about 350,000 individuals in the US, and 8 million in the Americas. To accomplish this, we will apply bacterial display peptide libraries, next-generation sequencing, and computational bioinformatics to identify a set of motifs and consensus peptides corresponding to antigenic peptide epitopes that when combined yield optimal sensitivity and specificity values in the discovery set. The motif and peptide panels will be validated using an independent specimen set. Assay reproducibility and stability will be measured. This project may thus lead to clinically useful tests to improve the rates of detection parasitic diseases their resultant complications.

Public Health Relevance

A majority of individuals with chronic parasitic infections are undiagnosed. In particular, an estimated 350,000 individuals in the US are chronically infected with T. cruzi, the causative agent of Chagas disease. Although molecular diagnostics are available to detect Chagas and other parasitoses, they lack the ability to be parallelized into a single testing assay that could be deployed broadly to screen at risk populations for these clinically important diseases. The proposed project aims to develop the capability to detect tens of different potential parasitic infectious using a single blood test, and could be expanded to many other infectious diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI129113-01
Application #
9255416
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Pesce, John T
Project Start
2017-01-01
Project End
2017-06-30
Budget Start
2017-01-01
Budget End
2017-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Serimmune, Inc.
Department
Type
DUNS #
079520932
City
Goleta
State
CA
Country
United States
Zip Code
93117